Actions following adverse drug events – how do these influence uptake and utilisation of newer and/or similar medications?

Table 1 Timeline of regulatory and public subsidy decisions for COX-2 inhibitors in Australia

1999	Jun	Regulatory authority approved celecoxib for marketing in Australia
	Oct	Regulatory authority approved rofecoxib for marketing in Australia
2000	Jun	Rofecoxib recommended to be subsidized on the PBS as a treatment for osteoarthritis only
	Aug	Celecoxib listed on the PBS
2001	Feb	Rofecoxib listed on the PBS
	Sep	Regulatory authority approved meloxicam for marketing in Australia
2002	Feb	Meloxicam listed on the PBS
2004	Jul	Regulatory authority approved lumiracoxib for marketing in Australia
	Sept	Rofecoxib withdrawn from the Australian market
2006	Aug	Lumiracoxib listed on the PBS
2007	Aug	Lumiracoxib withdrawn from the Australian market

ISSN: 1472-6963